Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
F 6.79 -1.59% -0.11
QURE closed down 1.59 percent on Thursday, September 28, 2023, on 58 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -1.59%
Slingshot Bearish Bearish Swing Setup -2.02%
Wide Bands Range Expansion -2.02%
Oversold Stochastic Weakness -2.02%
New 52 Week Closing Low Bearish -0.88%
New 52 Week Low Weakness -0.88%
Wide Bands Range Expansion -0.88%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 12 hours ago
Down 3% about 12 hours ago
Down 2 % about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago
New 52 Week Low about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


uniQure N.V. Description

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Disease Clinical Development Genetics Gene Therapy Parkinson's Disease Metabolic Disease Applied Genetics Gene Delivery Hemophilia Lipoprotein Treatment Of Hemophilia Adeno Associated Virus Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B Lipase Lipoprotein Lipase Deficiency

Is QURE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.255
52 Week Low 6.67
Average Volume 962,607
200-Day Moving Average 16.79
50-Day Moving Average 8.53
20-Day Moving Average 7.58
10-Day Moving Average 7.20
Average True Range 0.39
RSI (14) 29.08
ADX 40.98
+DI 11.60
-DI 32.00
Chandelier Exit (Long, 3 ATRs) 7.93
Chandelier Exit (Short, 3 ATRs) 7.84
Upper Bollinger Bands 8.65
Lower Bollinger Band 6.51
Percent B (%b) 0.13
BandWidth 28.17
MACD Line -0.55
MACD Signal Line -0.54
MACD Histogram -0.012
Fundamentals Value
Market Cap 302.13 Million
Num Shares 44.5 Million
EPS -2.80
Price-to-Earnings (P/E) Ratio -2.43
Price-to-Sales 368.82
Price-to-Book 9.86
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.17
Resistance 3 (R3) 7.17 7.04 7.10
Resistance 2 (R2) 7.04 6.95 7.04 7.08
Resistance 1 (R1) 6.92 6.89 6.86 6.92 7.06
Pivot Point 6.79 6.79 6.76 6.79 6.79
Support 1 (S1) 6.67 6.70 6.61 6.67 6.52
Support 2 (S2) 6.54 6.64 6.54 6.50
Support 3 (S3) 6.42 6.54 6.48
Support 4 (S4) 6.42